NO20005833D0 - Humaniserte antistoffer som gjenkjenner verotoksin II og cellelinje som produserer det samme - Google Patents

Humaniserte antistoffer som gjenkjenner verotoksin II og cellelinje som produserer det samme

Info

Publication number
NO20005833D0
NO20005833D0 NO20005833A NO20005833A NO20005833D0 NO 20005833 D0 NO20005833 D0 NO 20005833D0 NO 20005833 A NO20005833 A NO 20005833A NO 20005833 A NO20005833 A NO 20005833A NO 20005833 D0 NO20005833 D0 NO 20005833D0
Authority
NO
Norway
Prior art keywords
verotoxin
humanized antibodies
recognize
produce
same
Prior art date
Application number
NO20005833A
Other languages
English (en)
Other versions
NO20005833L (no
NO326197B1 (no
Inventor
Yoh-Ichi Matsumoto
Atsuchi Imaizumi
Tsuyoshi Kimura
Tae Takedo
Man Sung Co
Maximiliano Vasques
Original Assignee
Teijin Ltd
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Ltd, Protein Design Labs Inc filed Critical Teijin Ltd
Publication of NO20005833D0 publication Critical patent/NO20005833D0/no
Publication of NO20005833L publication Critical patent/NO20005833L/no
Publication of NO326197B1 publication Critical patent/NO326197B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20005833A 1998-05-20 2000-11-17 Humaniserte antistoffer, fremgangsmate for deres fremstilling, farmasoytisk preparat, anvendelse samt cellelinje NO326197B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8657098P 1998-05-20 1998-05-20
PCT/US1999/011179 WO1999059629A1 (en) 1998-05-20 1999-05-19 Humanized antibodies that recognize verotoxin ii and cell line producing same

Publications (3)

Publication Number Publication Date
NO20005833D0 true NO20005833D0 (no) 2000-11-17
NO20005833L NO20005833L (no) 2001-01-15
NO326197B1 NO326197B1 (no) 2008-10-13

Family

ID=22199443

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005833A NO326197B1 (no) 1998-05-20 2000-11-17 Humaniserte antistoffer, fremgangsmate for deres fremstilling, farmasoytisk preparat, anvendelse samt cellelinje

Country Status (19)

Country Link
US (1) US7846435B1 (no)
EP (1) EP1079856B1 (no)
JP (1) JP4044733B2 (no)
KR (1) KR100548167B1 (no)
CN (1) CN1330375C (no)
AT (1) ATE335504T1 (no)
AU (1) AU748852B2 (no)
BR (1) BR9910589A (no)
CA (1) CA2328485C (no)
DE (1) DE69932719T2 (no)
DK (1) DK1079856T3 (no)
ES (1) ES2270598T3 (no)
IL (2) IL139571A0 (no)
NO (1) NO326197B1 (no)
NZ (1) NZ508119A (no)
PT (1) PT1079856E (no)
RU (1) RU2217166C2 (no)
WO (1) WO1999059629A1 (no)
ZA (1) ZA200006370B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910096B2 (en) 1996-11-15 2011-03-22 Trustees Of Tufts College Human neutralizing antibodies against hemolytic uremic syndrome
US8293245B2 (en) 2006-04-20 2012-10-23 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on Shiga toxin type 1 protein
WO2010085539A1 (en) 2009-01-23 2010-07-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on shiga toxin type 2 protein
WO2014191904A1 (en) * 2013-05-27 2014-12-04 Inmunova S.A. Antibodies which bind specifically the b subunit of the shiga toxin
US10167333B2 (en) * 2014-01-16 2019-01-01 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis B virus surface antigen

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP3236667B2 (ja) 1991-06-28 2001-12-10 三菱化学株式会社 ヒト型モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ並びに抗腫瘍剤
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
AU667533B2 (en) 1992-03-26 1996-03-28 Microcarb, Inc. Monospecific polyclonal antibodies to shiga-like toxins
CA2078716A1 (en) 1992-09-21 1994-03-22 Joyce De Azavedo Attaching and effacing protein of enterohemorrhagic e. coli
US5747272A (en) 1994-02-14 1998-05-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine Detection of shiga-like toxins of enterohemoragic Escherichia coli
CA2116179C (en) 1994-02-22 2008-01-08 C. A. Lingwood Verotoxin pharmaceutical compositions and medical treatments therewith
CA2218601A1 (en) 1995-03-24 1996-10-03 Ophidian Pharmaceuticals, Inc. Treatment for verotoxin-producing escherichia coli
CA2163716C (en) 1995-11-24 2009-05-19 Clifford A. Lingwood Verotoxin pharmaceutical compositions and medical treatments therewith
DE19641466A1 (de) 1996-10-09 1998-04-16 Biotest Pharma Gmbh Orale Anwendung eines Immunglobulinpräparates zur Prävention des Hämolytischen Urämischen Syndroms sowie Präparat hierfür
WO1998020903A1 (en) * 1996-11-15 1998-05-22 Trustees Of Tufts College Humanized neutralizing antibodies against hemolytic uremic syndrome
US20030170248A1 (en) * 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease

Also Published As

Publication number Publication date
PT1079856E (pt) 2006-12-29
JP2002515230A (ja) 2002-05-28
HK1036215A1 (en) 2001-12-28
DE69932719T2 (de) 2007-09-13
JP4044733B2 (ja) 2008-02-06
CA2328485C (en) 2011-05-03
IL139571A (en) 2009-09-22
NO20005833L (no) 2001-01-15
IL139571A0 (en) 2002-02-10
NO326197B1 (no) 2008-10-13
RU2217166C2 (ru) 2003-11-27
EP1079856A1 (en) 2001-03-07
DE69932719D1 (de) 2006-09-21
AU748852B2 (en) 2002-06-13
NZ508119A (en) 2003-06-30
KR100548167B1 (ko) 2006-01-31
CN1330375C (zh) 2007-08-08
CN1301175A (zh) 2001-06-27
US7846435B1 (en) 2010-12-07
ATE335504T1 (de) 2006-09-15
ZA200006370B (en) 2001-08-22
EP1079856B1 (en) 2006-08-09
KR20010052367A (ko) 2001-06-25
DK1079856T3 (da) 2006-12-04
AU4090499A (en) 1999-12-06
EP1079856A4 (en) 2002-03-13
WO1999059629A1 (en) 1999-11-25
CA2328485A1 (en) 1999-11-25
BR9910589A (pt) 2001-01-16
ES2270598T3 (es) 2007-04-01

Similar Documents

Publication Publication Date Title
TR200103756T2 (tr) Hümanize anti-ErbB2 antikorları ve anti-ErbB2 antikorlarıyla tedavi.
EP2363404A3 (en) PSMA antibodies
TNSN08255A1 (en) Anti-mn antibodies and methods of using same
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
TR200200472T2 (tr) Anti-Erb B2 antikorları ile tedavi için dozajlar
DE69732868D1 (de) Mittel gegen Juckreiz
ATE461220T1 (de) Anti-egfr-antikörper
DE69531679D1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
CY1110894T1 (el) Μεθοδοι για θεραπεια ή προληψη αγγειακης φλεγμονης χρησιμοποιωντας αναστολεα (-εις) απορροφησης στερολης
BR0309254A (pt) Uso de um anticorpo anti-ctla-4
ATE294591T1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
NO20054351L (no) Monoklonalt antistoff og hybridom som produserer dette
IL139700A0 (en) Immunotherapeutic composition and method for the treatment of prostate cancer
ATE509955T1 (de) Humanisierte kollagen-antikörper und damit verbundene verfahren
DE60210413D1 (de) Zusammensetzungen zur immunisierung sowie deren verwendung
DK1572087T3 (da) Antistoffer med cancerantigen TMEFF2 og anvendelser deraf
ATE353920T1 (de) Menschlischer monoklonaler antikörper gegen ep- cam und dessen verwendung in krebstherapie
NO20010747D0 (no) Antitrombotisk middel og humanisert anti-von Willebrand faktor monoklonalt antistoff
NO20005833D0 (no) Humaniserte antistoffer som gjenkjenner verotoksin II og cellelinje som produserer det samme
NO980251L (no) Behandling av konsentrasjonssvikt/hyperaktivitetsforstyrrelse
WO2003072727A3 (en) EGFRvIII SPECIFIC MONOCLONAL ANTIBODY AND EGFRvIII RIBOZYMES AND USE TO DETECT, TREAT OR PREVENT EGFRvIII ASSOCIATED CANCER
TR200001290T2 (tr) Estrojen mahrumiyet sendromunu tedavi etmek için yararlı 2-aril-3-aroilbenzo(b) tiofenler.
DK1629009T3 (da) Sammensætninger omfattende store og små bindefragmenter af antistoffer rettet imod det samme toksin
DK1100829T3 (da) Anvendelse af basiliximab til behandling af rheumatoid arthritis eller hudsygdomme
ATE323289T1 (de) Auf tsap6-bindungspartnern beruhendes screeningverfahren

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees